10-Q: Foghorn Therapeutics Narrows Q3 Loss, Advances Lilly Programs

Foghorn Therapeutics Inc. reported a reduced net loss for the nine months ended September 30, 2025, driven by decreased operating expenses and continued progress in its collaboration with Eli Lilly and Company.

Summary

• Net loss for the nine months ended September 30, 2025, was $52.6 million, an improvement from $67.1 million for the same period in 2024.
• Collaboration revenue increased to $21.7 million for the nine months ended September 30, 2025, up from $19.7 million in 2024, attributed to continued advancement of programs under the Lilly Collaboration Agreement.
• Research and development (R&D) expenses decreased by $10.6 million to $63.4 million for the nine months ended September 30, 2025, primarily due to the discontinuation of independent development for FHD-286 and FHD-609.
• General and administrative (G&A) expenses decreased by $1.253 million to $20.8 million for the nine months ended September 30, 2025, mainly due to reduced professional and consulting costs and lease modifications.
• Cash, cash equivalents, and marketable securities totaled $180.3 million as of September 30, 2025.
• The accumulated deficit reached $610.8 million as of September 30, 2025.
• The Phase 1 dose escalation study of FHD-909, a selective allosteric ATPase inhibitor of SMARCA2 developed in collaboration with Lilly, dosed its first patient in October 2024, with costs expected to increase with enrollment.
• A new 10-year lease agreement for 72,846 square feet of laboratory and office space in Watertown, Massachusetts, was entered into in June 2025, with commencement expected in the fourth quarter of 2025.
• The existing Office Lease was amended in June 2025, resulting in a reduction of lease payments of $8.5 million and shortened terms for portions of the leased space.

Sentiment

Score: 6

Explanation: The company shows improved financial performance with a reduced net loss and increased collaboration revenue, indicating effective cost management and progress in its key partnership with Eli Lilly. The strategic decision to discontinue less promising independent programs is a prudent financial and strategic move. The cash runway of at least 12 months provides stability. However, the company remains in a clinical stage with a substantial accumulated deficit and explicitly states the need for significant additional funding in the future, which introduces potential dilution risk. The long-term success hinges on the successful clinical development and commercialization of its product candidates, which remains highly uncertain and subject to significant industry-specific risks. Given the mixed signals of financial improvement and ongoing capital needs, the sentiment is neutral to slightly positive.

Positives

• Net loss significantly decreased for both the three-month ($15.8 million vs. $19.1 million) and nine-month ($52.6 million vs. $67.1 million) periods compared to the prior year, indicating improved financial performance.
• Collaboration revenue increased to $21.7 million for the nine months ended September 30, 2025, reflecting continued progress and value generation from the Eli Lilly partnership.
• Research and development expenses decreased by $10.6 million for the nine months, primarily due to the strategic decision to discontinue independent development of FHD-286 and FHD-609, allowing for focused resource allocation.
• The initiation of the Phase 1 dose escalation study for FHD-909, a key Lilly-partnered program, in October 2024 represents significant clinical advancement.
• Cash, cash equivalents, and marketable securities of $180.3 million as of September 30, 2025, are expected to fund operating expenses and capital expenditure requirements for at least 12 months, providing near-term liquidity.

Negatives

• The company continues to incur significant operating losses, with an accumulated deficit of $610.8 million as of September 30, 2025.
• Interest income decreased due to a lower average balance of marketable securities during the period.
• The discontinuation of independent development for FHD-286 and FHD-609 indicates pipeline rationalization, which may reflect challenges or a reprioritization of assets.
• Sublease income decreased due to the conclusion of one sublease on April 28, 2025.
• The company explicitly states the need for substantial additional funding beyond the next 12 months to support its continuing operations and growth strategy.

Risks

• Dependence on key individuals for successful operations.
• The need to develop commercially viable products and obtain regulatory approval, which is uncertain.
• Competition from other companies, many of whom are larger and better capitalized.
• The need to obtain adequate additional financing, which may not be available on acceptable terms or at all.
• Potential adverse effects of financing terms on stockholders' holdings or rights.
• The possibility of being forced to delay, reduce, or eliminate research and development programs or commercialization efforts if funding is insufficient.
• Inability to accurately predict the timing or amount of increased expenses or when profitability will be achieved.
• Risks associated with pharmaceutical product development, including clinical trial outcomes.
• Geopolitical events and uncertainty, including effects of a prolonged U.S. government shutdown and armed conflicts, impacting financial and economic conditions.
• Reliance on contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), including those located outside the United States.
• The ability to attract and retain key scientific and management personnel.
• The scope of protection for intellectual property rights covering product candidates and the Gene Traffic Control platform.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future, with expenses and capital requirements anticipated to increase substantially as it advances its programs into clinical development, identifies new product candidates, protects intellectual property, expands its platform, and seeks marketing approvals. It will not generate revenue from product sales until successful commercialization and regulatory approval, and expects significant expenses for commercialization capabilities if products are approved. Substantial additional funding will be required to support continuing operations and growth strategy beyond the next 12 months, with an inability to accurately predict the timing or amount of increased expenses or when profitability will be achieved due to pharmaceutical development risks and the current geopolitical and economic environment.

Management Comments

• "We expect that our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months."
• "We will need substantial additional funding to support our continuing operations and pursue our growth strategy."
• "We are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability."

Industry Context

Foghorn Therapeutics operates in the highly competitive clinical-stage biopharmaceutical industry, characterized by high research and development costs, lengthy development timelines, and significant regulatory hurdles. Its focus on the chromatin regulatory system represents a novel and potentially differentiating therapeutic approach in oncology. The strategic collaboration with Eli Lilly and Company is a common industry practice for early-stage biotech firms, enabling shared development costs and leveraging the expertise and resources of a major pharmaceutical partner. The decision to discontinue independent development programs (FHD-286, FHD-609) aligns with industry norms for pipeline rationalization, allowing the company to focus resources on the most promising assets in a capital-intensive environment. The company's acknowledgment of geopolitical and economic uncertainties reflects broader macroeconomic pressures impacting the entire biopharmaceutical sector.

Comparison to Industry Standards

• The collaboration with Eli Lilly and Company is a strong industry validation, indicating confidence from a major pharmaceutical company in Foghorn's Gene Traffic Control platform and the SMARCA2 program (FHD-909).
• The decision to discontinue independent development of FHD-286 and FHD-609 is a standard practice in the biopharmaceutical industry, reflecting data-driven pipeline management and resource allocation, aligning with industry norms for clinical-stage companies facing high R&D costs and capital constraints.
• The company's cash runway of 'at least 12 months' is a common metric for clinical-stage biotech companies, and while adequate for the short term, the explicit need for 'substantial additional funding' is typical for companies that are not yet profitable and are advancing costly clinical programs.

Legal Proceedings

• Not currently a party to any material litigation or legal proceedings that are probable to have a material adverse effect on the business.

Related Party Transactions

• A consulting agreement with a scientific founder (who is also a shareholder) resulted in payments of $0.1 million for the nine months ended September 30, 2025.
• Eli Lilly and Company, a 5% or greater shareholder, is a related party due to the collaboration agreement. Payments to Lilly totaled $4.2 million for the nine months ended September 30, 2025, with a payable of $4.0 million due to Lilly as of September 30, 2025.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future capital raises; positive impact from reduced losses and advancement of key partnered programs; negative impact from substantial accumulated deficit and ongoing operational losses.
• **Employees:** Decreased headcount in research and development functions noted, but plans to hire additional R&D personnel are mentioned, indicating a shift in workforce allocation.
• **Eli Lilly (Collaboration Partner):** Continued collaboration and cost-sharing for the FHD-909 program, indicating ongoing commitment and potential for future milestone and royalty payments.
• **Creditors/Suppliers:** Normal course of business operations with accounts payable and accrued expenses being managed.

Next Steps

• Advance FHD-909 and other product candidates partnered with Lilly, and continue preclinical and clinical development of product candidates from the current portfolio.
• Identify and advance additional research programs and product candidates.
• Initiate preclinical testing for any new product candidates identified and developed.
• Obtain, maintain, expand, enforce, defend, and protect trade secrets and intellectual property portfolio.
• Hire additional research and development personnel.
• Add operational, legal, compliance, financial, and management information systems and personnel to support research, product development, and operations.
• Expand the capabilities of the Gene Traffic Control platform.
• Acquire or in-license product candidates, intellectual property, and technologies.
• Seek marketing approvals for any product candidates that successfully complete clinical trials.
• Ultimately establish a sales, marketing, and distribution infrastructure to commercialize any products for which marketing approval may be obtained.
• Account for the new Watertown lease as a right-of-use asset and lease liability at the time the landlord makes the premises available (expected in Q4 2025).
• Remeasure the term for contingent early terminations of other portions of the Office Lease when the contingencies are resolved (expected in Q4 2025).

Key Dates

Recommendation

The company demonstrates improved financial performance with a reduced net loss and increased collaboration revenue, indicating effective cost management and progress in its key partnership with Eli Lilly. The strategic decision to discontinue less promising independent programs (FHD-286, FHD-609) allows for a more focused allocation of resources towards the most promising assets, particularly the Lilly-partnered FHD-909. The cash runway of at least 12 months provides near-term stability. However, the company remains in a clinical stage with a substantial accumulated deficit and explicitly states the need for significant additional funding in the future, which introduces potential dilution risk. The long-term success hinges on the successful clinical development and commercialization of its product candidates, which remains highly uncertain and subject to significant industry-specific risks. Given the mixed signals of financial improvement and ongoing capital needs, a 'Hold' recommendation is appropriate for investors to monitor further clinical progress and capital allocation strategies.

Keywords

Biopharmaceutical, Oncology, Gene Traffic Control, Chromatin Regulatory System, Clinical-stage, FHD-909, SMARCA2, Eli Lilly, Drug development, Biotech, SEC filing, 10-Q, Financial results